Astellas reports, Xtandi sales in focus for Medivation


Astellas Pharma (ALPMY.PK) reports FQ1 consolidated net sales of ¥275.8B (.pdf), up 13.4% Y/Y.

Net sales of Xtandi — the prostate cancer treatment developed and commercialized with partner Medivation (MDVN) —  were $82M for the period, below Street estimates of $83.7M. (supplemental documents)

Xtandi faces what some say is looming threat from Janssen's acquisition of Aragon and the company's ARN-509.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs